Geovax Labs Inc's Comment on Sales, Marketing and Customers
The company operates in a competitive landscape that includes large multinational pharmaceutical firms such as Sanofi, GSK, Merck, Mitsubishi Tanabe, Takeda, and Pfizer; mid-size pharmaceutical and emerging biotechnology companies including Dynavax, Novavax, Moderna, BioNTech, and Bavarian Nordic; as well as academic and not-for-profit researchers like the NIH. The global market features over forty authorized COVID-19 vaccines, including three available in the U.S. from Pfizer/BioNTech, Moderna, and Novavax. Development of therapeutic vaccines and immunotherapies for cancer involves companies such as Advaxis, Immune Design, Oncothyreon, Bavarian Nordic, Roche Pharmaceuticals, Merck, Bristol Myers Squibb, and AstraZeneca. For hemorrhagic fever viruses, both development-stage and established companies include NewLink Genetics, Merck, Johnson & Johnson, Novavax, Inovio, and GlaxoSmithKline. The FDA approved the first Ebola Zaire vaccine, ERVEBO®, developed by Merck, in December 2019. Customers and markets referenced include Advaxis, AstraZeneca, Bavarian Nordic, BioNTech, Bristol Myers Squibb, Dynavax, GlaxoSmithKline, GSK, Immune Design, Inovio, Johnson & Johnson, Merck, Mitsubishi Tanabe, Moderna, NewLink Genetics, NIH, Novavax, Oncothyreon, Pfizer, Roche Pharmaceuticals, Sanofi, and Takeda.
Geovax Labs Inc’s Comment on Sales, Marketing and Customers
The company operates in a competitive landscape that includes large multinational pharmaceutical firms such as Sanofi, GSK, Merck, Mitsubishi Tanabe, Takeda, and Pfizer; mid-size pharmaceutical and emerging biotechnology companies including Dynavax, Novavax, Moderna, BioNTech, and Bavarian Nordic; as well as academic and not-for-profit researchers like the NIH. The global market features over forty authorized COVID-19 vaccines, including three available in the U.S. from Pfizer/BioNTech, Moderna, and Novavax. Development of therapeutic vaccines and immunotherapies for cancer involves companies such as Advaxis, Immune Design, Oncothyreon, Bavarian Nordic, Roche Pharmaceuticals, Merck, Bristol Myers Squibb, and AstraZeneca. For hemorrhagic fever viruses, both development-stage and established companies include NewLink Genetics, Merck, Johnson & Johnson, Novavax, Inovio, and GlaxoSmithKline. The FDA approved the first Ebola Zaire vaccine, ERVEBO®, developed by Merck, in December 2019. Customers and markets referenced include Advaxis, AstraZeneca, Bavarian Nordic, BioNTech, Bristol Myers Squibb, Dynavax, GlaxoSmithKline, GSK, Immune Design, Inovio, Johnson & Johnson, Merck, Mitsubishi Tanabe, Moderna, NewLink Genetics, NIH, Novavax, Oncothyreon, Pfizer, Roche Pharmaceuticals, Sanofi, and Takeda.
Sources:
Geovax Labs Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Geovax Labs Inc’s corporate clients.
For your research, we’ve provided 9 tables on Geovax Labs Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
